BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 17, 2025
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Jan. 13, 2021

View Archived Issues
Ocular-eye

Glaukos reports 12-month data for Istent Infinite glaucoma therapy

Glaukos Corp. reported 12-month results from the pivotal IDE trial of its Istent Infinite trabecular micro-bypass system, showing substantial reduction in mean diurnal intraocular pressure (IOP) in patients with open-angle glaucoma uncontrolled by prior surgery or medication. The company is targeting U.S. FDA approval of the device for standalone moderate-to-severe glaucoma in late 2021. Read More
opportunity-future-telescope.png

Panelists make predictions on digital health investment in 2021

What is the outlook for investment in digital health over the coming year? A group of investment experts tackled that question during a session of the Digital Medicine & Medtech Showcase, which is being held virtually this week. Although COVID-19 was disruptive, there was a huge increase in health innovation investment last year, with a jump of roughly 56%, said Logan Plaster, director and editor-in-chief at Startup Health. Read More
Coronavirus vs US

Stenzel: Developers should track impact of new SARS variants on single-target assays

Reports of multiple new variants of the SARS-CoV-2 virus have emerged, raising questions about the efficacy of vaccines, but also regarding the utility of diagnostic and other tests. The U.S. FDA’s Tim Stenzel said single-target tests are thus at a greater risk of returning a false negative result, adding that these developers “should consider this carefully” in surveillance of their tests. Read More
Kidney-dialysis-AI.png

Renalytix and Davita join forces to identify and manage early-stage kidney disease

Diagnostics innovator Renalytix AI plc and dialysis giant Davita Inc. partnered to develop a program to identify individuals with early-stage kidney disease and improve outcomes for the 37 million Americans with chronic kidney disease (CKD). The companies plan to launch the collaborative effort in three cities in 2021 to build a diverse, real-world evidence dataset as a base for moving forward. Read More
Australia-flag-health-tech.png

Australia advances infrastructure investments in diabetes, cardiovascular, regenerative therapies

PERTH, Australia – Australia’s Medical Technologies and Pharmaceuticals Industry Growth Center (MTPConnect) is boosting funding for the translation and commercialization of research in diabetes, cardiovascular disease and regenerative medicine. Read More

Appointments and advancements for Jan. 13, 2021

New hires and promotions in the med-tech industry, including: Axol, Clinical Laserthermia, Healthtronics, Labminds, Mentice, Moon Surgical, Nanoview, Outset Medical, Rapid Medical, Rapid Micro Biosystems, Spineology, Vironix. Read More

Financings for Jan. 13, 2021

Med-tech firms raising money in public or private financings, including: Huami, Oncolens, Predictive Oncology, Promaxo. Read More

In the clinic for Jan. 13, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acarix, Exact Sciences, Glaukos, Nexstim, Lumiradx. Read More

Other news to note for Jan. 13, 2021

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: A2 Biotherapeutics, Allergan Aesthetics, Biodesix, Cypris Medical, Daxor, Dermtech, Elixir Medical, Exact Sciences, Genscript USA, Hibercell, Invitae, L1 Enterprises, Lifenet Health, Nile AI, Nuvo Group, Oxford Immunotec Global, Pacific Biosciences, Personal Genome Diagnostics, Promega, Qiagen, Robocath, Retia Medical, Scapa Healthcare, Tempus, UCB, Valneva, Vivalnk. Read More

Regulatory actions for Jan. 13, 2021

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Excalibur Healthcare Services, Siemens Healthineers, Vestibular First. Read More

Regulatory front for Jan. 13, 2021

The latest global regulatory news, changes and updates affecting medical devices and technologies, including: New test beats biopsy for transplant rejection; NICE eyes digital health HTAs; MHRA moves on the hazards of bedrails; TGA zeroes in on tests for COVID-19; HHS posts rule for agency enforcement action. Read More

BioWorld MedTech’s Orthopedics Extra for Jan. 13, 2021

Keeping you up to date on recent developments in orthopedics, including: New treatment allows some people with spinal cord injury to regain hand and arm function; Scientists reveal how gut microbes can influence bone strength in mice; New drug form may help treat osteoporosis, calcium-related disorders; Hip fracture incidence expected to increase substantially in some Eurasian countries. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 17, 2025.
  • IPO puzzle pieces

    Medline raises $6.3B in fourth med-tech IPO of December

    BioWorld MedTech
    Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 17, 2025.
  • Child pushing away bowl of peanuts

    Vitesse finesse pays off: DBV wins in peanut allergy phase III

    BioWorld

    DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....

  • IPO stock market ticker

    Acryl raises $28M IPO, aiming to bridge medical divide with AI

    BioWorld MedTech
    Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing